Published in Hepatitis Weekly, February 21st, 2005
The companies will continue their joint efforts to identify novel small molecule therapeutics for the treatment of hepatitis C virus infections (HCV) for an additional 12 months, through December 2005.
Under the extension, which was permitted under the terms of the existing agreement, Merck will continue to contribute drug candidates to the collaboration and fund Metabasis' efforts to apply its technologies to those candidates with the goal of producing a candidate suitable for clinical...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.